Danaher Corporation (dhr)
DHR — Company Overview
Danaher Corporation (DHR) is a large-cap company in the Healthcare sector, operating in Diagnostics & Research.
| Ticker | DHR |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Exchange | NYQ |
| Market cap | $140.58B |
| Last price | $199.98 |
| Size category | Large Cap |
DHR — Business Description
Danaher Corporation (DHR) operates in Diagnostics & Research within the broader Healthcare market. Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of fu…
Official website: https://www.danaher.com.
DHR — Investment Thesis
The investment thesis for Danaher Corporation (DHR) rests on how Healthcare dynamics, profitability, and valuation interact at today's price.
- Revenue is expanding at roughly 5.5% year-over-year (public data).
- Trailing P/E of 35.65× implies elevated growth expectations at the current price.
- Forward P/E (21.51×) is below trailing P/E — earnings may be expected to improve.
- Dividend yield near 0.8% adds an income component to total return.
- Equity market capitalization is approximately $140.58B.
Analyst consensus, price targets & estimates is available in Vest Terminal for Professional and Enterprise subscribers.
DHR — Financial Health
Financial health for Danaher Corporation (DHR) is summarized from publicly reported profitability, leverage, and cash-flow metrics.
Profit margin of 15.9% indicates solid bottom-line conversion. Positive free cash flow of $4.33B supports balance-sheet flexibility.
| Trailing P/E | 35.65× |
| Forward P/E | 21.51× |
| Price / Sales | 5.60× |
| Price / Book | 2.67× |
| Gross margin | 58.8% |
| Operating margin | 19.8% |
| Profit margin | 15.9% |
| Return on equity | 7.6% |
| Debt / Equity | 52.97 |
| Free cash flow | $4.33B |
DHR — Growth Outlook
Growth outlook for Danaher Corporation (DHR) depends on demand trends in Diagnostics & Research and the company's ability to convert revenue into sustainable earnings.
- Revenue growth of 5.5% suggests steady but measured expansion.
- Earnings growth of 59.7% year-over-year supports improving profitability.
- Price is 17.6% below the 52-week high.
- Shares trade 24.3% above the 52-week low — limited rebound so far.
DHR — Competitive Position
Danaher Corporation (DHR) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.
- Competes within Healthcare, specifically in Diagnostics & Research.
- Market capitalization of $140.58B places DHR among large-cap peers.
- Gross margin near 58.8% may reflect pricing power or favorable mix.
DHR — Strengths
Strengths for Danaher Corporation (DHR) inferred from public financial metrics:
- Revenue growth of 5.5% year-over-year.
- Earnings growth of 59.7% year-over-year.
- Gross margin of 58.8% supports competitive unit economics.
- Positive free cash flow ($4.33B).
- Moderate leverage (debt/equity 52.97).
- Large Cap scale ($140.58B) may provide distribution and funding advantages.
DHR — Weaknesses
Weaknesses and pressure points for Danaher Corporation (DHR) based on available data:
- Elevated trailing P/E (35.65×) limits valuation margin of safety.
DHR — Opportunities
- Trading 24.3% above the 52-week low — potential recovery if fundamentals stabilize.
- Positive free cash flow enables reinvestment, debt reduction, or shareholder returns.
- Forward earnings multiple below trailing P/E — potential earnings acceleration ahead.
DHR — Risks
- Standard market, regulatory, competitive, and execution risks apply to all public equities.
DHR — Summary
Danaher Corporation (DHR) is a large-cap Healthcare company focused on Diagnostics & Research, listed on NYQ. Last price $199.98 with market cap $140.58B. Trailing P/E 35.65×. Revenue grew 5.5% year-over-year per public data. Notable strengths include revenue growth of 5.5% year-over-year. Key watch items include elevated trailing p/e (35.65×) limits valuation margin of safety. Detailed estimates, ownership, and news for Danaher Corporation remain locked in Vest Terminal for subscribers.
Danaher Corporation FAQ
What does Danaher Corporation (DHR) do?
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology s…
What is DHR's P/E ratio?
Danaher Corporation has a trailing P/E of 35.65× based on publicly available market data.
Does DHR pay a dividend?
Indicated dividend yield: 0.8%. Confirm ex-dates and payout history in Vest Terminal.
What sector is DHR in?
Danaher Corporation is classified in Healthcare (Diagnostics & Research) on NYQ.
What is DHR's market capitalization?
Approximate market cap: $140.58B.
What are the main risks for DHR?
Key risks include elevated valuation, among factors on this page.
What are the strengths of DHR?
Potential positives include revenue growth of 5.5% year-over-year, earnings growth of 59.7% year-over-year.
Where can I get analyst estimates for DHR?
Consensus estimates, price targets, and detailed analyst data for Danaher Corporation are available to Professional subscribers in Vest Terminal — not on this public summary page.